<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00091052</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000383147</org_study_id>
    <secondary_id>SIRIUS-1053285</secondary_id>
    <secondary_id>SIRIUS-01</secondary_id>
    <nct_id>NCT00091052</nct_id>
  </id_info>
  <brief_title>Radiation Therapy and Sargramostim in Treating Patients With Advanced Solid Tumors</brief_title>
  <official_title>Contrast-Enhanced Radiotherapy With GM-CSF Immune Stimulation - Phase I/II Clinical Center Treatment Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sirius Medicine</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Colony-stimulating factors such as sargramostim increase the number of immune&#xD;
      cells found in bone marrow or peripheral blood. Radiation therapy uses high-energy x-rays to&#xD;
      damage tumor cells. Combining radiation therapy with sargramostim may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects of giving radiation therapy&#xD;
      together with sargramostim and to see how well it works in treating patients with advanced&#xD;
      solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the safety of contrast-enhanced high-dose radiotherapy administered with&#xD;
           sargramostim (GM-CSF) in patients with advanced solid malignancies.&#xD;
&#xD;
        -  Determine immune response in patients treated with this regimen.&#xD;
&#xD;
        -  Determine tumor response in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: Patients are stratified according to prior therapy (biopsy or simple surgery vs&#xD;
      radical surgery, chemotherapy, or radiotherapy).&#xD;
&#xD;
      Patients receive a contrast agent intratumorally followed by a single fraction of kilovoltage&#xD;
      radiotherapy. Beginning 24 hours after radiotherapy, patients receive sargramostim (GM-CSF)&#xD;
      intratumorally continuously for 1 week and then subcutaneously for 2 weeks. Patients with&#xD;
      lung tumors receive GM-CSF by inhalation twice daily for 1 week and then every other week for&#xD;
      a total of 3 weeks of drug treatment.&#xD;
&#xD;
      Treatment may repeat in several weeks in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      Patients are followed every 8 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 47 patients (12 for phase I and 35 for phase II) will be&#xD;
      accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">June 2006</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity as measured by the Southwest Oncology Group Performance Status and Toxicity Criteria on day 1 and in weeks 4, 12, and 20</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune and tumor response as measured by reverse transcriptase polymerase chain reaction (RT-PCR) and CT scan on day 1 and in weeks 2, 3, 4, 12, and 20 or weeks 4, 12, and 20</measure>
  </secondary_outcome>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed solid malignancy&#xD;
&#xD;
               -  Advanced disease&#xD;
&#xD;
          -  Radiotherapy is appropriate treatment (i.e., radio-responsive)&#xD;
&#xD;
               -  No tumors beyond the reach of kilovoltage beam (e.g., &gt; 15 cm beneath the skin)&#xD;
&#xD;
          -  At least 1 lesion accessible to needle localization and catheter placement&#xD;
&#xD;
          -  May be refractory to prior chemotherapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  0-4&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 2 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL (RBC transfusion allowed)&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3 (transfusion independent)&#xD;
&#xD;
          -  No excessive leukemic blasts&#xD;
&#xD;
          -  No bleeding diathesis&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  PT and PTT ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST or ALT &lt; 2 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase &lt; 2 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine &lt; 1.5 mg/dL&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  No contraindication to MRI or CT scan&#xD;
&#xD;
          -  No medical or psychiatric condition that would preclude giving informed consent&#xD;
&#xD;
          -  Able to lie flat for 1 hour&#xD;
&#xD;
          -  No known hypersensitivity to sargramostim (GM-CSF) or any of its components&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Prior biologic therapy allowed&#xD;
&#xD;
          -  No concurrent biologic therapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Concurrent hormonal therapy allowed&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Prior radiotherapy to planned treatment site allowed&#xD;
&#xD;
          -  No other concurrent radiotherapy to planned treatment site&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Prior surgery allowed&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 14 days since prior radiosensitizers&#xD;
&#xD;
          -  No other concurrent investigational therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael D. Weil, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sirius Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sirius Medicine, LLC</name>
      <address>
        <city>Loveland</city>
        <state>Colorado</state>
        <zip>80538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2006</verification_date>
  <study_first_submitted>September 7, 2004</study_first_submitted>
  <study_first_submitted_qc>September 7, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2004</study_first_posted>
  <last_update_submitted>March 25, 2013</last_update_submitted>
  <last_update_submitted_qc>March 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2013</last_update_posted>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

